Successful completion of the EU-GMP Audit at its Amritsar General and Beta Lactam Units
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kwality Pharmaceuticals announced the successful completion of the European Union Good Manufacturing Practices (EU-GMP) audit at its Amritsar manufacturing facilities, covering both the General and Beta-Lactam units. The audit concluded with no major observations, confirming compliance with international quality standards. With this achievement, the company now has four EU-approved facilities — General, Beta-Lactam, Cephalosporin, and Oncology — strengthening its capability to serve regulated international markets across multiple therapeutic areas and dosage forms.
This is a positive regulatory milestone that strengthens the company's credibility for exports to EU and other regulated markets, potentially supporting future revenue growth from international business, though no immediate financial impact is disclosed.